These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
628 related articles for article (PubMed ID: 29748390)
21. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911 [TBL] [Abstract][Full Text] [Related]
22. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. Lalani AA; Xie W; Martini DJ; Steinharter JA; Norton CK; Krajewski KM; Duquette A; Bossé D; Bellmunt J; Van Allen EM; McGregor BA; Creighton CJ; Harshman LC; Choueiri TK J Immunother Cancer; 2018 Jan; 6(1):5. PubMed ID: 29353553 [TBL] [Abstract][Full Text] [Related]
23. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830 [TBL] [Abstract][Full Text] [Related]
24. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945 [TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Ding L; Dong HY; Zhou TR; Wang YH; Yan T; Li JC; Wang ZY; Li J; Liang C Cancer Med; 2021 Sep; 10(18):6384-6401. PubMed ID: 34382349 [TBL] [Abstract][Full Text] [Related]
26. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518 [TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136 [TBL] [Abstract][Full Text] [Related]
28. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Zhu Z; Jin Y; Zhou J; Chen F; Chen M; Gao Z; Hu L; Xuan J; Li X; Song Z; Guo X Mol Cancer; 2024 Jul; 23(1):146. PubMed ID: 39014460 [TBL] [Abstract][Full Text] [Related]
29. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features. Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490 [TBL] [Abstract][Full Text] [Related]